Bicara Therapeutics Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Bicara Therapeutics Inc. (BCAX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $38.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- Bicara Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $38.80M, a 82.16% increase from fiscal 2024.
- Bicara Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $21.30M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $38.80M 10-K · filed 2026-03-30 |
| 2024-12-31 | $21.30M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |